Akebia Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Akebia Therapeutics

06/05/2025 13:38

Akebia Therapeutics Inc AKBA.OQ AKBA.O is expected to show a rise in quarterly revenue when it reports  results on May 8 for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report a 37.6% increase in revenue to $44.883 million from $32.61 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Akebia Therapeutics Inc is for a loss of 4 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Akebia Therapeutics Inc is $6.75​, above​ its last closing price of $2.34. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.09
-0.08
-0.10
Missed
-25
Sep. 30 2024
-0.07
-0.06
-0.10
Missed
-57.9
Jun. 30 2024
-0.05
-0.05
-0.04
Beat
25​
Mar. 31 2024
-0.08
-0.08
-0.09
Missed
-17.4
​​Dec. 31 2023
-0.04
-0.04
0.00
Beat
100
Sep. 30 2023
-0.07
-0.08
-0.08
Met
5.9​
Jun. 30 2023
-0.02
-0.02
-0.06
Missed
-140
Mar. 31 2023
-0.15
-0.15
-0.14
Beat
6.7

This summary was machine generated May 6 at 12:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)